Search

You searched for "BSoT"

24 results found

BCG strain differences have an impact on clinical outcome in bladder cancer immunotherapy

1 March 2015 | | URO - Urologic Oncology
Bacillus Calmette-Guérin (BCG) has been part of the treatment algorithm for non-muscle invasive bladder cancer (NMIBC) for a number of years. In this single centre, prospective, randomised trial, two of the most commonly available strains, BCG Connaught and BCG Tice,...

The Urology Foundation – 2019 Report

11 December 2019
It has been another busy year for The Urology Foundation in our mission to end the suffering caused by urology disease. We’ve taken big strides in some of the most crucial areas of our work as we work to prevent, treat and cure all urology disease.

BAUS 2023 Annual Scientific Meeting

4 May 2023 |
BAUS June 2022 was certainly noteworthy for me personally, as Tim O’Brien passed on the baton of Presidency. It was also a very special meeting for everyone who participated. The event felt so refreshing after two years of COVID and...

An overview of changes to urology training

1 January 2017 | | URO - Core Urology
Paediatric urology training A review of paediatric emergency services in the UK involving general surgery, urology and paediatric surgery was initiated due to the problems encountered by the lack of suitable experience outside large paediatric surgical units to deliver emergency...

The life of a urology trainee in Singapore

1 November 2014 | | URO - Core Urology
Despite the political and cultural differences between the United Kingdom and Singapore, the quality and nature of the medical training systems remain uniquely similar. It will come as no surprise to those of you who have either worked in Singapore...

OCERT: a new multi-specialty project to standardise robotic surgical training

3 June 2020 | | URO - Urologic Oncology, URO - Technology
Since its introduction by Dr William Osler in 1890 to the Board of Trustees at John Hopkins Hospital [1], the Halstedian ‘See one, do one, teach one’ has represented a guideline for surgeons worldwide, both for open and laparoscopic surgery,...

Burnout: is this just a pandemic phenomenon?

28 July 2022 |
The phrase ‘burnout’ is often heard, but what is it, and what are the early warning signs? Importantly, how can it be prevented or managed? Over the last few years, health professional wellbeing, mental health, and burnout have come to...

In conversation with Mary Garthwaite

30 August 2024 | URO - Core Urology
We were delighted to chat with Mary Garthwaite, former Consultant Urological Surgeon and Chair of The Urology Foundation, the UK’s only charity representing all urological cancers and conditions. Can you tell us a little bit about what led you into...

BAUS 2024 - Welcome from the Honorary Secretary

3 May 2024
Joe Philip. I am thrilled to extend a warm welcome to each and every one of you as we gear up for what promises to be an enriching and enlightening conference experience. On behalf of Mo Belal, the remarkable events...

Surgical video – part 2: Tips on how to edit and create a finished surgical video for teaching or publication

1 November 2015 | | URO - Technology
A well-made and informative video can be one of the most valuable promotional tools for a department of urology. Having to resort to an external commercial source to produce a video can be prohibitively expensive. With the extensive computing power...

Neuromodulation for lower urinary tract dysfunction – an ICS update

1 July 2018 | | URO - Functional / Reconstructive Urology, URO - Technology
Non-invasive and invasive electro-stimulation techniques have been extensively studied in the treatment of lower urinary tract and bowel dysfunction, including overactive bladder syndrome (OAB), non-obstructive chronic urinary retention, faecal incontinence and chronic pelvic pain. Currently, the most common indication for...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | URO - Basic Science Research, URO - Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...
  • 1
  • 2 (current)